Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT05384769
Official study title

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

Study summary

This clinical trial investigates how practical and doable (feasibility) cell-free deoxyribonucleic acid (DNA) liquid biopsy is in screening high-risk patients for lung cancer. Currently, a low dose computed tomography (CT) scan is used to screen for lung cancer, however, due to various factors, few high-risk patients are screened. Liquid biopsy utilizes technology that can detect small amounts of DNA shed by cancer cells and may be able to spot lung cancer at an earlier stage. If a positive result comes back from the liquid biopsy, a patient may be more willing to get a low dose CT (LDCT) scan, possibly confirming the biopsy's findings and thus leading to more early lung cancer detection.

Ask AI to explain this study
Start here

Key things to know

Main goalScreening

This describes the study’s primary purpose.

What is being studiedLiquid Biopsy and Low Dose Computed Tomography of the Chest

Plus 1 other study approaches.

Who it may be forLung Carcinoma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 7, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?City of Hope Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
City of Hope Medical Center
Interventions being studied
Procedure: Liquid Biopsy; Procedure: Low Dose Computed Tomography of the Chest; Other: Survey Administration
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Documented written informed consent of the participant.
  • Age 50-80 years.
  • Smoking history of \>= 20 pack-years and if quit, quit within 15 years.
  • Received referral for counseling for lung cancer screening and would qualify for LDCT.
  • Health Insurance that will pay for a LDCT for lung cancer screening at either City of Hope Duarte, Newport Beach (Newport Diagnostic Imaging), or Lancaster (Renaissance Imaging/Antelope Valley Outpatient Imaging Center).
  • Willingness to provide blood sample.
  • English speaking.
  • Consent to undergo lung cancer screening with either liquid biopsy (LB) or LDCT.
Reasons someone may not be able to joinExclusion criteria
  • Symptoms of lung cancer.
  • Chest CT scan or chest positron emission tomography (PET)/CT within 12 months.
  • Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer.
  • Unable to undergo LDCT at either City of Hope Duarte, Newport Beach, or Lancaster.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • City of Hope Medical CenterDuarte, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 7, 2026. Always confirm current availability with the study team.

View original record ↗